Drug Database
CE

cerebroprotein hydrolysate for injection (III)

✓ Approved

ApicHope Pharmaceutical · Polypeptide · Polypeptide

What is cerebroprotein hydrolysate for injection (III)?

cerebroprotein hydrolysate for injection (III) is a polypeptide developed by ApicHope Pharmaceutical. It is approved for therapeutic indications via injectable (others).

Drug Profile

CompanyApicHope Pharmaceutical
Drug ClassPolypeptide
RouteInjectable (Others)
StatusApproved
Sources: ClinicalTrials.gov, ApicHope Pharmaceutical

Therapeutic Indications

cerebroprotein hydrolysate for injection (III) is developed for 3 unique indications across 3 therapeutic areas.

Therapeutic AreaConditionPhase
Nervous system disordersAmnesia✓ Approved
Injury, poisoning and procedural complicationsCraniocerebral injury✓ Approved
Psychiatric disordersAttention deficit hyperactivity disorder✓ Approved

Related Research Articles

PubMedEsophagus : official journal of the Japan Esophageal Society2026-09-20

Local triamcinolone acetonide injection for the prevention of pharyngeal deformity following endoscopic submucosal dissection of superficial pharyngeal neoplasms.

Suzuki Yugo Y, Oda Minoru M, Tanaka Junji J, Kikuchi Daisuke D et al.

Extensive mucosal resection following endoscopic submucosal dissection (ESD) for hypopharyngeal neoplasms can result in scar contracture and pharyngeal deformity, potentially increasing the risk of aspiration pneumonia. This study aimed to evaluate the efficacy and safety of local triamcinolone acetonide (TA) injection for preventing post-ESD pharyngeal deformity. This retrospective cohort study included 388 patients who underwent ESD for hypopharyngeal neoplasms between 2011 and 2026. Patients were divided into those who received local TA injection after ESD (TA group, n = 65) and those who did not (control group, n = 323). Post-ESD pharyngeal deformity was classified into four grades based on endoscopic findings. The piriform sinus was subdivided into three subfields according to the extent of the mucosal defect. The TA group had a significantly lower deformity severity and fewer grade ≥ 2 deformities than the control group (both p < .001). Significant preventive effects were observed only in the piriform sinus (both p < .001). Among mucosal defects involving multiple piriform sinus subfields, both outcomes were significantly lower in the TA group for mucosal defects involving two (p < .001 and p = .046, respectively) and three (both p < .001) subfields. Similar findings were observed after propensity score matching. No adverse events related to TA injection were observed. Local TA injection may be an effective and safe strategy for preventing post-ESD pharyngeal deformity, particularly in mucosal defects involving multiple piriform sinus subfields.

PMID 42763380
Read full article →
PubMedEuropean radiology2026-09-20

Enhanced recurrence risk stratification for stages Ⅱ-Ⅲ breast cancer using MRI-based structure habitat imaging.

Wang Guangsong G, Shi Dafa D, Guo Qiu Q, Wang Rui R et al.

To identify robust tumor habitat subregions using pre-treatment MRI and assess the prognostic value of the resulting phenotypes for recurrence risk stratification in stages II-III breast cancer. This multicenter retrospective study included 842 women with stages II-III breast cancer who received pre-treatment MRI scans and subsequent surgical resection from three centers (multicenter discovery cohort: n = 415; external test cohort: n = 427). An unsupervised clustering-based habitat characterization framework was applied to delineate tumor subregions and identify distinct structure habitat phenotypes (SH-phenotypes). Recurrence-free survival (RFS) was evaluated using Kaplan-Meier analysis and multivariate Cox regression. Fine-Gray competing risk regression was additionally used to account for death as a competing event. Two structural subregions (central and peripheral) with unique radiomic patterns and three SH-phenotypes with distinct RFS were identified in the discovery cohort and validated in the test cohort (log-rank p < 0.001 for both). The SH-phenotypes remained independent prognostic predictors after adjustment for tumor size, nodal involvement, clinical subtype, pathological grade, and patient age [test cohort: SH-phenotype 2 vs 1, hazard ratio (HR) = 2.29, p = 0.048; SH-phenotype 3 vs 1, HR = 3.45, p = 0.006]. Similar results were obtained in the competing risk regression analysis. Two structural habitat subregions were identified, and the derived SH-phenotypes provide additional prognostic value beyond clinicopathological factors for recurrence risk stratification in stages II-III breast cancer. Question Precise evaluation of recurrence risk is crucial for tailoring therapy for stages II-III breast cancer, but it remains challenging with classical clinicopathological factors. Findings Pre-treatment MRI-based SH analysis identified three phenotypes with distinct RFS and recurrence cumulative incidence, independent of clinicopathological factors. Clinical relevance The clinical utility of this phenotyping lies in its role as an adjunct to classical clinicopathological factors, enhancing recurrence risk stratification for optimized treatment planning in stages II-III breast cancer.

PMID 42763333
Read full article →
PubMedOncoTargets and therapy2026-09-20

ctDNA in the Management of Resectable & Advanced Colorectal Cancer: Current Status and Future Directions.

Al-Shamsi Humaid O HO, Rafii Saeed S, Tirmazy Syed Hammad Hassan SHH, Mukherji Deborah D et al.

Circulating tumor DNA (ctDNA) is an increasingly important biomarker for molecular residual disease (MRD) after curative-intent treatment of colorectal cancer (CRC), but its prognostic value must be distinguished from proven clinical utility. This structured narrative review synthesizes evidence from PubMed/MEDLINE, Embase, ClinicalTrials.gov, and major oncology conference proceedings, covering stage I-III CRC and selected patients with resected or ablated oligometastatic stage IV disease. We review tumor-informed and tumor-agnostic assay strategies, postoperative sampling, serial versus landmark testing, low-shedding disease, clonal hematopoiesis, and major prospective and randomized studies. Postoperative ctDNA positivity consistently identifies patients at substantially increased risk of recurrence, while serial ctDNA dynamics provide additional prognostic information. In stage II colon cancer, the randomized DYNAMIC trial showed that a ctDNA-guided strategy reduced adjuvant chemotherapy use without compromising long-term recurrence outcomes. By contrast, DYNAMIC-III did not establish non-inferiority for ctDNA-guided de-escalation and showed no recurrence-free survival benefit from conventional chemotherapy escalation in ctDNA-positive stage III disease. The Phase III ALTAIR trial likewise did not meet its pre specified primary disease-free survival endpoint for treatment of molecular relapse with trifluridine/tipiracil. Current professional guidance therefore supports a cautious distinction between clinical validity and clinical utility: ctDNA can inform prognosis, counseling, and clinical-trial eligibility, but should not routinely replace standard surveillance or independently determine treatment escalation or de-escalation outside evidence-based indications or clinical trials. Future progress requires harmonized assays, randomized demonstration of outcome benefit, and prospective validation of integrated ctDNA, pathology, transcriptomic, and AI-derived risk models.

PMID 42763649
Read full article →
PubMedArthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association2026-09-20

Bone Marrow Aspirate Augmentation Reduces Reoperation Rates After Osteochondral Allograft Transplantation of the Knee: A Systematic Review.

Thamrongskulsiri Napatpong N, Morgan Jacob T JT, Casanova Felipe F, Moews Logan D LD et al.

To systematically review the clinical, radiographic, and patient-reported outcomes of osteochondral allograft (OCA) transplantation with versus without bone marrow aspirate (BMA) augmentation for the treatment of knee cartilage defects. A comprehensive search was performed according to the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Comparative clinical studies assessing OCA with and without BMA were included. Two reviewers independently performed screening, data extraction, and methodological quality assessment using the Cochrane Risk of Bias Tool 2.0 for randomized trials and the Methodological Index for Non-Randomized Studies for nonrandomized studies. Four studies (3 Level III, 1 Level I) involving 165 knees met the inclusion criteria. The mean follow-up duration across studies ranged from 5.5 to 18.0 months. Across 2 comparative studies, BMA augmentation was associated with fewer reoperations (2.4% vs 21.9%) compared with non-BMA augmentation. Radiographic findings were heterogeneous: 1 study showed earlier integration and reduced sclerosis with BMA at 6 months, whereas 2 magnetic resonance imaging-based studies showed no differences in OCA Magnetic Resonance Imaging Scoring System scores. Computed tomography assessment in 1 trial found increased small cysts but a trend toward fewer large cysts in BMA-treated grafts. Patient-reported outcomes from 1 study showed no significant differences in International Knee Documentation Committee or Knee injury and Osteoarthritis Outcome Score for Joint Replacement scores between groups, although achievement of the Knee injury and Osteoarthritis Outcome Score for Joint Replacement minimal clinically important difference favored the BMA cohort (88% vs 55%; P = .076). OCA transplantation augmented with BMA is associated with significantly lower reoperation rates compared with nonaugmented transplantation. Although short-term radiographic data show improved early subchondral remodeling, these findings are not consistently corroborated by magnetic resonance imaging-based scores. Level III, systematic review of Level I and III studies.

PMID 42763432
Read full article →
PubMedArthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association2026-09-20

Labral Repair and Reconstruction Yield Comparable Patient-Reported Outcomes at Short- to Mid-Term Follow-Up During Primary Hip Arthroscopy: A Systematic Review.

Messer Kyle P KP, Pinchok Alicia R AR, Hernandez Evan J EJ, Dhillon Jaydeep J et al.

To systematically review and compare clinical outcomes and survivorship of labral repair versus labral reconstruction during primary hip arthroscopy. A search of PubMed, the Cochrane Library, and Embase databases was performed using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Comparative clinical studies investigating labral repair versus reconstruction during primary hip arthroscopy were included. Outcomes assessed included patient-reported outcomes (PROs), rate of revision hip arthroscopy, and conversion to total hip arthroplasty. Six Level III studies met inclusion criteria (1628 labral repairs, 679 reconstructions). Mean age at surgery ranged from 29.9 to 48.6 years (repair) and 34.6 to 48.1 years (reconstruction). Mean follow-up ranged from 2.0 to 5.8 years. All studies showed significant within-group improvements in PROs with minimal clinically important difference and patient acceptable symptomatic state achievement rates exceeding 70% in both groups, with no significant between-group differences. Two studies found no significant differences in postoperative PROs or magnitude of improvement between groups. Conversely, 2 studies showed greater mean PRO improvement in the reconstruction group, including patients aged ≥40 years in 1 study, while 1 study reported higher adjusted postoperative PROs for labral repair. Four studies showed no significant differences in revision rates, but 1 reported a lower total hip arthroplasty conversion rate after labral repair, and 1 reported a lower failure rate with reconstruction in patients aged ≥40 years. Both labral repair and reconstruction show significant improvements in PROs at short- to mid-term follow-up, with comparable achievement of minimal clinically important difference and patient acceptable symptomatic state thresholds. However, evidence suggests that labral repair yields lower rates of conversion to total hip arthroplasty, whereas reconstruction offers better clinical outcomes and lower failure rates in patients aged ≥40. Consequently, the optimal surgical approach should be individualized based on patient age, intraoperative assessment of tissue quality, and overall joint pathology. Level III, systematic review of Level III studies.

PMID 42763809
Read full article →
PubMedAnesthesiology and pain medicine2026-09-20

Enhanced Delivery of Transforaminal Epidural Steroid Injection (TFESI) for Radiculopathy Associated with Acute Lumbar Disc Prolapse Through Physiotherapist-led Assessment, Consent, and Direct Listing.

Mattocks Greta G, Meshykhi Layla L, Thornton Benjamin B, Goebel Andreas A et al.

Invasive treatments for lumbar radiculopathy with persistent symptoms and concordant disc prolapse include a transforaminal epidural steroid injection (TFESI) and microdiscectomy. Evidence supports TFESI as a potential first-line alternative to surgery. Our expedited nerve root block service (ERBS) reduced progression to surgery; however, waiting times remained suboptimal. We evaluated a streamlined pathway incorporating physiotherapy-led consent and direct TFESI listing. This retrospective observational study evaluated a pathway modification in which the pre-procedure specialist consultation was removed. Two Musculoskeletal Clinical Assessment Service (MCAS) physiotherapists were trained to assess suitability, obtain consent, and list patients directly for TFESI, with consultant validation conducted virtually. The primary outcomes were the median waiting time from MCAS consent to TFESI and the change in waiting time compared with the previous pathway. Secondary outcomes were the proportion of listings validated, patient-reported response to TFESI, progression to surgery, and the association between TFESI response and disc pathology. A total of 129 patients provided consent (mean age, 47.3 ± 12.7 years; 95% confidence interval (CI), 45.1 - 49.5; 63.6% female), with 100% validation. The median waiting time from MCAS consent to TFESI was 50 days (range, 2 - 262 days), representing a 37-day reduction (43%) compared with the previous pathway. A positive TFESI response occurred in 83% of patients, and 14% required microdiscectomy. Response rates were similar for disc protrusion (84%) and extrusion (81%). A physiotherapy-led ERBS pathway was associated with reduced waiting times and no identified safety concerns, while maintaining a low conversion rate to surgery.

PMID 42763667
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about cerebroprotein hydrolysate for injection (III)